台博会是服务台商台企开拓内销、转型升级的"金字招牌"。本届台博会由广东省人民政府台湾事务办公 室、东莞市人民政府、全国台湾同胞投资企业联谊会联合主办，以"强链融合，未来"为主题，参展企业 达671家，展位1881个，规模再创历史新高。 近年来，根据《东莞深化两岸创新发展合作总体方案》的"四新定位"，东莞出台系列政策措施，发挥海 峡两岸青年创业基地和莞台青少年交流活动的桥梁作用，越来越多岛内年轻人将未来发展的目光投向广 东、投向东莞。 南方财经记者程浩 东莞报道 9月11日，2025第十六届东莞台湾名品博览会（下称"台博会"）开幕。省、市领导，中央台办经济局及 省委台办领导，来自两岸工商团体和东南亚地区的台商台企代表等共600多人共同见证盛会开幕。 值得注意的是，今年东莞台博会首次设立"亚洲台商主题馆"，邀请了印度、马来西亚、泰国、越南等地 的实力台企参展，进一步扩大了展会的影响力与"朋友圈"。 建文卷门集团公司来自马来西亚，此次带来具备全球首创设计的防火钢板门、防火隔热卷动折叠墙等产 品。深耕安全领域近70年，建文卷门公司希望借助台博会这一平台，在中国市场深化经贸合作、产业对 接，发现新商机、新渠道。 "台博 ...

Group 1 - The 2025 Dongguan Taiwan Products Expo features a record scale with 671 participating companies and 1881 exhibition booths, showcasing various high-tech products and Taiwanese delicacies [1][3][15] - The expo aims to enhance the integration of Taiwanese businesses into the new development landscape and promote high-quality development, expanding the exhibition area from 32,000 square meters to 33,000 square meters [3][5] - The introduction of the "Asian Taiwanese Business Theme Pavilion" marks the first participation of brands from Thailand, India, Malaysia, and Vietnam, further broadening the expo's influence [5] Group 2 - The high-throughput chemical synthesis platform, showcased by Dongguan Qingyu Runda New Materials Technology Co., is an AI-integrated device that automates chemical synthesis, improving research efficiency and reducing labor costs [7][9] - The magnetic traction pipeline inspection robot, presented by Dongguan University of Technology, offers enhanced safety and energy efficiency compared to traditional inspection methods [9][11] - The Taiwanese delicacies section, featuring products like pomelo and pineapple cakes, has seen significant sales, with one exhibitor selling 400-500 boxes of pomelo in just one morning [13][15]

Summary of Chengdu XianDao Conference Call Company Overview - Chengdu XianDao has diversified its global market presence, with the US market accounting for nearly 50% of revenue, strong growth in Europe, and domestic market revenue increasing to around 15% [2][4] - The company has over 600 formal clients and more than 2000 potential partners, including large multinational corporations and biotechnology firms [2][6] Financial Performance - In the first half of 2025, Chengdu XianDao's revenue grew by 17% year-on-year, with overseas market growth reaching 21% [3] - Net profit attributable to shareholders increased by nearly 400%, marking a historical high, while non-recurring net profit surged over 2000% [3] - The overall gross margin rose by 7 percentage points to 53%, with healthy margins across various technology sectors [11] Market and Client Structure - The company has seen a significant increase in domestic market revenue share from less than 5% to approximately 15% in recent quarters [4] - Emerging markets in Japan and South Korea are becoming more active, expected to account for 5% to 8% of revenue [4] Core Technology Platforms - Chengdu XianDao's four core technology platforms (L+SVD, OBT+TBD) have achieved over 40% growth, particularly in the molecular glue sector [2][7] - The Open Deal 5.0 initiative has received positive feedback from emerging biotech companies and academic institutions in the US [7] M&A and Synergy Effects - The acquisition of FBDD has begun to show synergy effects, with Welais achieving profitability in the first half of the year [8] - The company is actively seeking M&A opportunities to strengthen existing core businesses and explore new technologies [22] Future Growth and Development Plans - Chengdu XianDao plans to maintain stable growth in its main business over the next 3-5 years, focusing on custom library development and expanding nucleic acid synthesis and optimization services [5][16] - The company is also investing in the protein degradation field and building peptide libraries to meet growing market demand [17] Challenges and Innovations - The small nucleic acid field faces challenges in delivery systems, particularly in crossing barriers like the blood-brain barrier [18] - Chengdu XianDao is leveraging AI technology to optimize molecular screening and reduce the time from target identification to clinical candidates [19] Clinical Pipeline and Projects - The small molecule pipeline is progressing well, with project 146 for solid tumors entering Phase II clinical trials [15][33] - The company is also focusing on clinical projects in cardiovascular, metabolic, inflammation, and pain areas, with plans to submit new IND applications [32] Cost Management and Financial Outlook - R&D expenses are expected to remain around 15%, with management expenses decreasing by 5% year-on-year [26] - The company aims to reduce management expense ratios to industry median levels as revenue scales up [26] Conclusion - Chengdu XianDao is positioned for long-term growth through strategic market expansion, technological innovation, and a robust clinical pipeline, while actively managing costs and exploring M&A opportunities to enhance its competitive edge [39]